Dr. Huang on Research in ALK+ NSCLC

Video

Chao H. Huang, MD, FACP, discusses ongoing research around the use of ALK inhibitors for non–small cell lung cancer.

Chao H. Huang, MD, FACP, associate professor of medical oncology, The University of Kansas Medical Center, discusses ongoing research around the use of ALK inhibitors for non–small cell lung cancer (NSCLC).

Much of today’s research is focused on newer generations of ALK inhibitors, Huang says. Understanding the different mechanisms of resistance that arise is crucial when determining subsequent treatment options, Huang explains.

Some resistance mechanisms may not concern ALK genes at all, and other research is exploring MET inhibition, which has a different mode of action than ALK inhibition, Huang continues. Additional research is examining combination therapy with ALK and MET inhibitors as a potential means of overcoming resistance to ALK inhibitors.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD